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Abstract Sulfur amino acids are determinant for the
detoxification of paracetamol (N-acetyl-p-aminophe-
nol) through sulfate and glutathione conjugations.
Long-term paracetamol treatment is common in the
elderly, despite a potential cysteine/glutathione defi-
ciency. Detoxification could occur at the expense of
anti-oxidative defenses and whole body protein stores
in elderly. We tested how older persons satisfy the
extra demand in sulfur amino acids induced by long-
term paracetamol treatment, focusing on metabolic
and nutritional aspects. Effects of 3 g/day paracetamol
for 14 days on fasting blood glutathione, plasma
amino acids and sulfate, urinary paracetamol metab-
olites, and urinary metabolomic were studied in
independently living older persons (five women, five
men, mean (±SEM) age 74±1 years). Dietary intakes
were recorded before and at the end of the treatment
and ingested sulfur amino acids were evaluated.
Fasting blood glutathione, plasma amino acids, and
sulfate were unchanged. Urinary nitrogen excretion
supported a preservation of whole body proteins,
but large-scale urinary metabolomic analysis
revealed an oxidation of some sulfur-containing
compounds. Dietary protein intake was 13% higher
at the end than before paracetamol treatment. Final
sulfur amino acid intake reached 37 mg/kg/day. The
increase in sulfur amino acid intake corresponded
to half of the sulfur excreted in urinary paracetamol
conjugates. In conclusion, older persons accommo-
dated to long-term paracetamol treatment by in-
creasing dietary protein intake without any
mobilization of body proteins, but with decreased
anti-oxidative defenses. The extra demand in sulfur
amino acids led to a consumption far above the
corresponding population-safe recommendation.
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Introduction
Paracetamol (N-acetyl-p-aminophenol) is probably the
most widely used of all analgesics in the world (Prescott
2005). It is commonly prescribed for long-term therapy
in elderly, for joint problems such as arthritis and gout
(Chen et al. 1985). It is considered as a safe drug, which
is mainly eliminated in urines (85% to 95%; Forrest et al.
1982; Critchley et al. 1986). A small part is excreted
unchanged (5%); the major part is excreted as its
glucuronide conjugate (55%) followed by its sulfate
conjugate (30%). Glucuronide and sulfate conjugations
are referred as phase II reactions. The remaining is
converted to N-acetyl-p-benzoquinone imine (NAPQI)
by the cytochrome P-450 (CYP450) oxidase enzyme
system, a phase I reaction. This toxic metabolite is
rendered harmless by reduced glutathione (GSH, γ-
glutamyl-cysteinyl-glycine), the main intracellular anti-
oxidant compound. Degradation of GSH-paracetamol
conjugate leads to cysteine paracetamol (free, sulfate and
glucuronide forms) and N-acetylcysteine paracetamol
(mercapturic acid of NAPQI; Hart et al. 1982). The
metabolism of one single dose of 1 g paracetamol appears
similar in young adults (21 years) and in elderly (79 years)
man; nevertheless, the partial metabolic clearance of
sulfate conjugate and the renal clearance of unchanged
paracetamol is reduced in elderly (Miners et al. 1988).
This could be related not only to aging-associated low
capacity to detoxify drugs (Klotz 2009) but also to the
cysteine/GSH deficiency syndrome observed in elderly
(Maher 2005; Dröge 2005; Mercier et al. 2006).
Beyond the need of cysteine for protein synthesis, it
is required for other syntheses such as glutathione and
sulfate. Cysteine is provided by dietary protein intake,
its release from body proteins and from glutathione, and
also by its endogenous synthesis from methionine and
serine through the transsulfuration pathway. When the
endogenous disposal of cysteine is insufficient regard-
ing its metabolic utilizations, it becomes an indispens-
able amino acid (Obled et al. 2004). Considering that
about 40% of paracetamol is metabolized as sulfur-
containing compounds, the maximal therapeutic dose
of paracetamol (4 g/day) induces a theoretical extra
demand of 1.3 g/day cysteine (i.e., 18 mg/kg/day). This
is equivalent to an extra demand of 23 mg/kg/day
methionine (stoichiometry). This amount is obviously
high regarding the recommended population-safe in-
take of methionine, which has been evaluated at 21–
27 mg/kg/day in the absence of cysteine intake (Di
Buono et al. 2001; Kurpad et al. 2003). The prevalence
of protein-energy malnutrition increases with age and
reaches 4–10% in older persons living at home, 15–
38% in institutionalized persons and 30–70% in
hospitalized ones (Raynaud et al. 2007). Cysteine
requirement might be uncovered in long- term
paracetamol-treated older persons, potentially leading
to metabolic deteriorations.
Previous studies in animal models and adult persons
show that short and long-term paracetamol treatments
affects sulfur amino acid and glutathione metabolisms.
One single dose of paracetamol (2 g) decreases plasma
cysteine and GSH concentrations (Burgunder et al.
1989) and 1 g/day paracetamol oxidizes the plasma
cysteine/cystine redox potential (Mannery et al. 2010)
in young adult men. Paracetamol induces dose-
dependent stimulations of rates of turnover of cysteine
and glutathione in men (Lauterburg and Mitchell
1987). Increasing the dose from 0.5 to 3 g in adults
leads to a decrease in the partial metabolic clearances
of sulfate and glutathione conjugates, likely due to the
depletion of hepatic pools of GSH and sulfur donor (3′-
phosphoadenosine 5′-phosphosulfate, whose precursor
is inorganic sulfate) (Slattery et al. 1987). After long-
term paracetamol treatment, GSH concentration de-
creased in rat liver (Buttar et al. 1977) and in human
plasma (Trenti et al. 1992). Such a decrease should be
avoided in elderly, since a decrease in plasma or blood
red cells GSH concentration is associated with a lower
physical and cognitive health in that population (Julius
et al. 1994). Long-term paracetamol treatment increases
sulfur amino acid requirement. Indeed, rats and mice
chronically fed paracetamol failed to grow, this inhibi-
tion being dose-dependent and restored by the addition
of methionine or cysteine to the diet (allowing protein
accretion) (Reicks and Hathcock 1989; McLean et al.
1989). Aging aggravates paracetamol-induced alter-
ations: in comparison to young or adult mice, liver
GSH was low in old mice, and old mice fail to
normalize liver and kidney GSH concentrations after a
single administration of paracetamol (Chen et al. 1990;
Richie et al. 1992; Chen et al. 2000).
Older persons under long-term paracetamol treat-
ment appear to be at risk for nutritional and metabolic
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troubles. To our knowledge, that point has not been
investigated, despite the known bad impact of high drug
intake on nutritional status, especially in the frail ones
(Chen et al. 1985; Pickering 2004). We hypothesized
that usual sulfur amino acid intake of older persons
could be insufficient to support both physiological
needs and paracetamol detoxification. If they failed to
adapt through an increase in protein intake, deleterious
alterations in paracetamol metabolism, glutathione
status, and/or whole body protein stores would occur
and contribute to the development of the frailty
syndrome. The aim of the study was to study how
older persons adjust to a long-term paracetamol
treatment. The main targets were dietary intake, para-
cetamol metabolism, sulfur amino acid-related metab-
olism, urinary excretion of sulfur and nitrogen, and also
overall metabolism assessed by urinary metabolomic.
Subjects and methods
Subjects
Eleven persons aged >69 years suffering from
arthritic pain, and who were planned to be adminis-
tered paracetamol as an analgesic, were selected to
participate in the study by their physicians. The study
was then performed by the Clinical Trials Investiga-
tion Center. The main exclusion criterion was an
ongoing treatment with N-acetylcysteine. The study
protocol was approved by the local ethical committee,
and all volunteers signed an informed consent form
before the inclusion in the study. One subject was
excluded a posteriori because urine analysis revealed
paracetamol ingestion at baseline. This study has been
registered as ClinicalTrial.gov NCT01116596.
Study design
The subjects were treated with 3 g/day paracetamol for
14 days. They had not received any dietary recommen-
dations. At baseline and at d14, fasting blood samples
were collected into heparin-containing tube (5 ml) for
paracetamol quantification and into EDTA-containing
tube (5 ml) for other measurements. The former was
centrifuged, and plasma was frozen at −20°C until
measurement. An aliquot of the latter was rapidly
collected and frozen at −80°C until blood glutathione
quantification. Plasma was separated from the remain-
ing EDTA-blood then frozen at −80°C until sulfate and
amino acid quantifications. Urine was collected at
baseline (second morning urine) and 24-h urines were
collected on the fourteenth day of treatment for urinary
paracetamol metabolites quantification, large-scale
metabolomic analysis, total nitrogen and total sulfur
quantifications. Two 10-ml aliquots of each urine sample
were frozen at −20°C until analysis. Dietary intakes were
collected before and at the end of the treatment.
Dietary recordings
The 2 days before the beginning of the treatment and
the four last days of treatment, the volunteers had to
record their food intakes in a notebook. These data
have been checked with a dietician with the validated
photo album SUVIMAX (Hercberg et al. 1994; Le
Moullec et al. 1996). Then, the conversion of food
data in nutrients intakes has been performed using the
software Geni (Geni version 6.0, Micro6—Villers les
Nancy, France), which includes the dietary composi-
tion table REGAL (Favier et al. 1995). The dietary
intake in methionine plus cysteine has been evaluated
considering that proteins consumed by the French
population contain 35 mg sulfur amino acid/g protein
(Patureau Mirand 2003). Sulfur intake derived from
methionine and cysteine has been calculated assuming
that the methionine intake equals twice the cysteine
intake based on dietary protein compositions in amino
acids (Block and Weiss 1956).
Blood and plasma analyses
Plasma paracetamol concentrations were measured by
use of HPLC with a diode array detection and a limit of
quantification of 0.05 μg/ml (Di Pietra et al. 1996).
Total blood glutathione (reduced and oxidized) con-
centration was quantified spectrophotometrically using
a standard enzymatic recycling procedure and 5,5'-
dithio-bis-2-nitrobenzoic acid as oxidant (Malmezat et
al. 1998). Plasma sulfate concentration was determined
by turbidimetry using the QuantiChromTM sulfate
assay kit (Gentaur, Paris, France). Total non-protein
cysteine (cysteine plus cystine plus cysteine bound to
proteins via disulfide bridges) was measured by
colorimetry in plasma treated with dithiothreitol before
deproteinization (Gaitonde 1967; Malloy et al. 1981).
Plasma-free amino acids were quantified by ion-
exchange chromatography with post-column ninhydrin
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detection (Bio-Tek Instrument, Serlabo Technologies,
Entraigues sur la Sorgue, France).
Quantification of urinary paracetamol metabolites
Paracetamol and its sulfate conjugate were purchased
from Sigma Aldrich (L’Isle d’Abeau, France), glucu-
ronide paracetamol from Chemos GmBH (Regenstauf,
Germany), N-acetylcysteine paracetamol and cysteine
paracetamol from Toronto Research Chemical (Bris-
bane Road, Toronto, Canada). All these compounds
were quantified in urine using a liquid chromatography
(LC) Agilent 1100 HPLC system (Agilent Technolo-
gies, Palo Alto, CA, USA) coupled to a triple-
quadrupole mass spectrometer (MS) API 2000 (Ap-
plied Biosystems/MDS Sciex, Foster City, CA, USA),
equipped with an electrospray ionization source inter-
face operating in the positive mode. MS parameters
were optimized by direct infusion of standard solu-
tions. Maximum sensitivity was obtained for a capillary
voltage at 5,000 V, a source temperature at 450°C, and
GS1 and GS2 at 40 and 60, respectively. Each standard
was optimized one by one to obtain the best sensitivity.
Urine samples were tenfold diluted in water with
1 μg/ml of 4-4 amido phenyl aminothiazole as internal
standard. Injection volume was set at 10 μl. Chroma-
tographic separation was performed on an 150×2.1 mm
Atlantis dC18 column (Waters, Saint Quentin en
Yvelines, France), with particle size of 5 μm at a flow
rate of 200 μl/min. Urine samples were eluted from the
LC column using the following gradient: 0 to 5 min:
90%A; 5 to 15 min: 10 to 100%B, 15 to 25 min at 90%
A. Solvent A was water containing 0.01 mM ammoni-
um formiate, and solvent B was methanol.
Quantification was achieved by measuring product
ions (multiple reaction monitoring [MRM]) from the
fragmentation of the protonated [M+H]+molecules.
The collision energy potential and the collision exit
potential were then adjusted to optimize the signal for
the most abundant product (daughter) ions (m/z 152>
110 for paracetamol, m/z 271>140 for cysteine para-
cetamol, m/z 313>140 for N-acetylcysteine paraceta-
mol, m/z 152>110 for glucuronide paracetamol and
sulfate paracetamol and m/z 234>192 for the internal
standard) using nitrogen as the collision gas at a
pressure of 10–3 mbar. Quantification was performed
using calibration curves with external standards. The
mean variability of each standard across its calibration
curve (%) was 8.2±4.7 for paracetamol, 7.9±5.8 for
cysteine paracetamol, 14.2±7.5 for N-acetylcysteine
paracetamol, 13.9±10.2 for glucuronide paracetamol,
and 6.7±4.3 for sulfate paracetamol.
Glucuronide and sulfate conjugates of cysteine para-
cetamol were not commercially available. Therefore,
total free form was quantified after an enzymatic
hydrolysis of 40 μl of 10-time diluted urine with 20 μl
of Escherichia coli β-glucuronidase sulfatase (Sigma
Aldrich—L’Isle d’Abeau, France) in buffered medium
(0.2 M sodium acetate, pH 5) for 1.5 h, at 37°C. The
reaction mixture was then stopped with 140 μl of
methanol and centrifuged at 3,900×g for 5 min.
Twenty microliters of 10 μg/ml 4-4 amido phenyl
aminothiazole was added to 50 μl of the supernatant
and diluted in 200 μl water. Quantifications of para-
cetamol, cysteine paracetamol, and N-acetylcysteine
paracetamol were performed in hydrolyzed urines as
described above. The enzymatic procedure was vali-
dated by the fact that paracetamol in hydrolyzed urine
(1.06±0.14 mg/ml) was not significantly different from
the sum of free paracetamol and its sulfate and
glucuronide conjugates (1.11±0.16 mg/ml).
Metabolomics
Urinary metabolic profiles were determined by LC-
QToF using a metabolomic approach. This untargeted
method consisting in the simultaneous analysis of a
high number of metabolites allows determining most
of metabolic perturbations.
The urine samples (500 μl) were defrosted at room
temperature, centrifuged at 7,000×g for 5 min at 4°C,
and then diluted fourfold with distilled water. Chroma-
tography was performed with a Waters Acquity UPLC
system (Waters Corporation, Manchester, United King-
dom). The UPLC system was coupled to a Waters
Qtof-Micro equipped with an electrospray source and a
lockmass sprayer. The source temperature was set to
120°C with a cone gas flow of 50 l/h, a desolvation
temperature of 300°C, and a nebulization gas flow of
400 l/h. The capillary voltage was set at 3,000 V and
the cone voltage to 30 V. The mass spectrometric data
were collected in continuum full-scan mode with a
mass-to-charge ratio (m/z) of 100–1,000 from 0 to
22 min, in positive and negative modes. All analyses
were acquired by using the lockspray with a frequency
of 5 s to ensure accuracy. Leucine enkephalin was used
as the lock mass at a concentration of 0.5 ng/l (in
MeOH/water, 50/50 by vol with 0.1% formic acid).
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To avoid possible differences between sample
batches, a Latin square was carried out to obtain a
randomized list of samples for analysis. Separation was
carried out at 30°C using a 2.1×100 mmAcquity UPLC
BEH Shield RP18 column (Waters), with a particle size
of 1.7 μm at a flow rate of 0.4 ml/min. Sample was
eluted from the column using the following gradient: 0
to 2 min: 100% A; 2 to 7 min: 0 to 10% B; 7 to 22 min:
95% B. Solvent A was water and solvent B was
acetonitrile, both solvents containing 0.1% formic acid.
Injection volume was set to 8 μl.
The raw data were transformed to centroid mode
and mass corrected before being analyzed with
MarkerLynx Applications Manager v1.0. The liquid
chromatography–MS data were peak-detected and
noise-reduced for both the liquid chromatography
and MS components. Each peak in the resulting three-
dimensional data set was represented by retention
time (RT), m/z and its ion intensity in each sample.
The matrix obtained was filtered using a Student’s t
test to eliminate the background ions present in blank
samples, and then exported for statistical analysis.
Metabolite identification
Metabolites contributing to the discrimination between
baseline and d14 samples were identified on the basis of
their exact masses which were compared to those
registered in Kyoto Encyclopedia of Genes and Genomes
database (http://www.genome.jp/kegg/) or in the Human
Metabolome Database (www.hmdb.ca) (Wishart et al.
2007) and to those of expected metabolites of para-
cetamol as described in the literature (Johnson and
Plumb 2005; Chen et al. 2008). Identification was
confirmed using appropriate standards when available,
isotopic patterns and mass fragmentation analyses. For
unknowns, the number of plausible elemental composi-
tions may be restricted to a small number (or uniquely
identified) with the aid of additional chemical informa-
tion—e.g., the molecular formula of the parent and
knowledge of possible metabolic pathways.
Urinary nitrogen and sulfur
Nitrogen was quantified in thawed urines by the
Kjeldahl method (block digestion unit Kjeldatherm
and distillation system Vapodest, Gerhardt, Les
Essarts le Roi, France) and sulfur was quantified in
lyophilized urines by direct combustion and infrared
detection (Sulfur SC-144DR analyzer, LECO,
Garges-les-Gonesse, France).
Statistical analyses
Data are expressed as means±SEMs. The effect of
gender was analyzed using Student’s t test and the effect
of paracetamol treatment using Student’s t test for paired
data. Statistical significance was set at P<0.05 and
analyses were performed with StatView for Windows,
version 5 software (SAS Institute, Cary, NC).
Each ion obtained in the metabolomic data matrix
was tested for its significance. An ion was considered
significant if the Student’s t test for paired data
comparing baseline and d14 samples (P≤0.05).
Results
Subjects
Six women and five men were included in the study
but one woman was excluded a posteriori because
paracetamol metabolites were detected in the urine
collected before the treatment. The anthropometric
characteristics (Table 1) were not different between
women and men (expect a trend for a higher height in
men). None of other studied parameters was depen-
dent on gender; therefore, all subjects were pooled.
Subjects mean (±SEM, n=10) age was 74.0±1.2 years,
body weight 74.2±3.6 kg, height 165±3 cm and body
mass index 27.2±1.1 kg/m2. All of them were
suffering from joint pain treated with paracetamol.
Half of the patients had other drugs. These treatments
Female (n=5) Male (n=5) All (n=10)
Age (year) 75.8±0.9 72.2±2.0 74.0±1.2
Body weight (kg) 73.2±7.0 75.1±2.9 74.2±3.6
Height (cm) 160±4 170±3 * 165±3
Body mass index (kg/m2) 28.4±2.2 26.0±0.5 27.2±1.1
Table 1 Baseline character-
istics of subjects
Values are means±SEM
*P<0.1 (Student’s t test).
Trend to be different from
female values
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had been installed at least for the last 2 months and no
new drug was introduced during the course of the
protocol. The drug metabolized by one of the CYP450
variants of paracetamol metabolism were lansoprazole
(CYP3A), pantoprazol (CYP3A4), amlodipine
(CYP3A4), acénocoumarol (CYP1A2), venlafaxine
(CYP2D6 and CYP3A4), which is a weak enzymatic
inhibitor (no other enzymatic inducer nor inhibitory
was noted) (Zhao and Pickering 2011). Only one
patient had pravastatine, not significantly metabolized
by CYP450. Considering the long-term use of these
treatments, they are negligible regarding potential
interferences with paracetamol metabolism.
Dietary intakes
Subject total energy intake was unchanged by para-
cetamol treatment (Table 2); it equaled 23 kcal/kg/
day, corresponding to 1.4-time the basal energy
metabolism calculated from Harris and Benedict
equations (1,233±87 kcal/day). This is consistent
with the low level of physical activity of the subjects.
The mean amount of alcohol ingested before and at
the end of the treatment was low and none subject
could be considered at risk of significant interference
between alcohol and paracetamol detoxifications
(Prescott 2000). Total protein intake was 13% higher
at the end (1.06±0.7 g/kg/day) than before (0.93±
0.08 g/kg/day) paracetamol treatment. This was
mostly explained by an increased intake in animal
proteins, which are known to exhibit higher content in
sulfur amino acids than vegetable proteins. Indeed,
animal protein intake reached at least 42.6±3.3 g/day
before treatment and 52.8±3.2 g/day at the end of the
treatment, whereas vegetable protein intake attained at
least 18.8±1.6 and 20.6±1.7, respectively. Animal
and vegetable protein intakes could not be accurately
evaluated due to missing values for animal and
vegetal protein contents of some foods. Anyway,
based on the accurate determination of total protein
intakes, the estimated methionine plus cysteine intake
and the corresponding sulfur intake were 13% higher
at the end than before the treatment.
Blood paracetamol and glutathione, and plasma
amino acids and sulfates
Plasma paracetamol was undetectable (lower than
0.05 μg/ml) in baseline and d14 fasting blood
samples. Blood concentration of total (reduced and
oxidized) GSH was unaffected by paracetamol treat-
ment (Table 3). Plasma total free cysteine (cysteine
plus cystine plus cysteine linked to plasma proteins
by a disulfide bridge) and sulfates were unchanged by
the treatment. Amino acid profile was also unaffected
by paracetamol treatment (Table 3).
Urinary paracetamol metabolites, nitrogen, and sulfur
at d14
Urinary concentrations and quantities of all paracetamol
metabolites excreted at d14 are shown in Table 4. The
total amount of paracetamol recovered in 24-h urines
was 2.3±0.3 g. The fractional recovery of unchanged
paracetamol was 6.4±3.3% and those of paracetamol
as conjugates were the highest for glucuronide (65.3±
5.6%) followed by sulfate (17.7±3.0%), N-acetylcys-
teine (6.1±0.8%) and cysteine (4.5±0.4%). Cysteine,
excreted in all paracetamol conjugates, amounted
177±17 mg/day. Cysteine paracetamol was mainly
present as glucuronide and sulfate conjugates but
N-acetylcysteine paracetamol seemed to be poorly or
not conjugated. Sulfur contained in paracetamol
sulfate equaled 77±10 mg/day. Sulfur excretion
due to overall paracetamol detoxification amounted
124±13 mg/day, whereas total urinary sulfur
attained 624±64 mg/day. Total nitrogen excretion
amounted 12.4±1.2 g/day and nitrogen urinary
concentration was proportional to the sulfur one
(nitrogen (g/l)=19.6×sulfur (g/l), r2=0.87).
Baseline d14
Energy (kcal/day) 1,666±138 1,667±141
Alcohol (g/day) 7.2±4.4 4.8±2.1
Proteins (g/day) 68.4±5.3 77.2±4.8 *
Methionine and cysteine (g/day) 2.40±0.19 2.70±0.17 *
Sulfur from methionine and cysteine (mg/day) 562±44 634±39 *
Table 2 Dietary intakes
Values are means±SEM
*P=0.006 (Student’s t test
for paired values). Signifi-
cantly different from base-
line values
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Urinary metabolomic
Eleven metabolites acquired in positive and negative
modes were detected only at d14 (Table 5), 9 of them
were surely related to paracetamol metabolism: para-
cetamol, paracetamol sulfate, paracetamol glucuronide,
cysteine paracetamol, N-acetylcysteine paracetamol,
cysteine paracetamol glucuronide, 3-methoxy-
paracetamol glucuronide, 3-methoxy-paracetamol sul-
fate and the benzothiazine compound; the latter origi-
nated from deacetylated paracetamol (Chen et al. 2008).
The unknown metabolite with RT of 6.6 and m/z
449.045 was likely related to paracetamol detoxification,
since its fragmentation spectrum showed a paracetamol
Baseline (μmol/l) d14 (μmol/l)
Glutathione 1,021±79 995±72
Sulfate 382±45 333±32
Cysteine (cysteine+cystine+cysS-Sx) 356±23 353±17
Cystine 52±3 57±3
Serine 70±4 76±3
Taurine 59±4 52±3
Aspartic acid+Asparagine 64±4 71±4
Glutamic acid+Glutamine 655±40 747±30
Alanine 279±31 323±37
Glycine 181±29 193±18
Threonine 81±4 90±5
Phenylalanine 41±2 43±3
Tyrosine 48±4 49±4
Leucine 95±5 105±5
Isoleucine 47±3 53±3
Valine 174±10 188±9
Tryptophane 36±3 37±3
Proline 168±18 175±19
Lysine 127±8 136±6
Histidine 45±3 49±3
Arginine 50±4 53±4
Citrulline 29±3 32±2
Ornithine 46±3 47±3
Table 3 Blood glutathione,
and plasma sulfate and
amino acid concentrations
Values are means±SEM.
Methonine was not reported
due to its loss during the
extraction procedure prior to
amino acid analysis. Homo-
cysteine and cystathionine
were not quantifiable in
present amino acid analyses
Concentration (mg/l) Quantity in 24-h urines (mg/day)
Paracetamol 61.5±24.0 147±73
Paracetamol sulfate 351±48 650±86
Paracetamol glucuronide 1,975±360 3,584±653
Cysteine paracetamol 24.5±1.6 46.7±4.0
Total cysteine paracetamol a 127±17 228±25
N-acetylcysteine paracetamol 90.8±12.0 170±25
Total N-acetylcysteine paracetamola 107±11 195±17
Sulfur in paracetamol metabolites 67.7±8.1 124±13
Total sulfur 342±41 624±64
Total nitrogen 6,793±743 12,413±1,218
Tab l e 4 Pa r a c e t amo l
metabolites, sulfur and ni-
trogen in urines collected
over d14
Values are means±SEM
aQuantified after enzymatic
hydrolysis as described in
“Materials and methods”
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residue. The unidentified metabolite with RT of 9.3 and
m/z 198.063 was probably an endogenous metabolite
exhibiting an undetectable level before treatment. The
excretion of seven endogenous metabolites was in-
creased with paracetamol treatment, whereas urinary
levels of 15 endogenous metabolites were lower at d14
than before treatment (Table 6). Some of them contained
sulfur: homocysteine and the unknown metabolite with
RT of 6.9 and m/z 410.018 decreased with paracetamol
treatment, whereas dimethyl sulfone and methionine
sulfoxide increased. Unknown metabolites in Table 6
did not show any cysteine or N-acetyl-cysteine residues
in their fragmentation spectra.
Discussion
Older persons are particularly exposed to the adverse
effect of medication on the nutritional status (Chen et
al. 1985; Pickering 2004). We have reported for the
first time how independently living patients adjusted
to a paracetamol curative treatment lasting 14 days.
The excretion of paracetamol and more precisely of
paracetamol sulfate was found lower than expected.
Despite a large loss of sulfur in urinary paracetamol
metabolites, morning blood glutathione, plasma sul-
fates and amino acids were not significantly affected
by the treatment. Paracetamol treatment induced a
spontaneous increase in dietary proteins leading to an
increase in sulfur intake corresponding to half of
paracetamol-induced sulfur loss. The large-scale
metabolomic analysis indicates that long-term para-
cetamol treatment induced few metabolic perturba-
tions, of which an increased oxidation of some sulfur-
containing compounds.
Paracetamol metabolism in older persons
Recovery of paracetamol in 24-h urines at d14 was
presently 77% of the daily dose. This value was lower
than the 85% to 95% of recovery in the urine within 24 h
observed in healthy adult subjects after a single
therapeutic dose (Forrest et al. 1982). It is unlikely that
absorption of paracetamol was affected in elderly, since
it occurs by passive transport (Forrest et al. 1982).
Since the therapeutic dosage was reported to be
carefully applied, the low paracetamol recovery may
be explained by an increased elimination through the
bile, a decrease in renal excretion due to the aging-
associated diminution in renal function (Zhou et al.
2008), or a prolonged retention in the body due to
overwhelmed detoxification capacities. The latter point
is supported by the low excretion of paracetamol
sulfate, which represented less than 20% of paracetamol
excreted in urine, whereas it usually amounted to 30%
(Forrest et al. 1982; Critchley et al. 1986). A low partial
metabolic clearance of paracetamol sulfate has already
been reported in elderly (Miners et al. 1988). The lower
excretion of paracetamol as sulfate conjugate was
compensated by a higher excretion as glucuronide
conjugate, which represented 65% of paracetamol
excreted in urine, whereas it usually amounts 55%
(Forrest et al. 1982; Critchley et al. 1986). The intense
glucuronidation of paracetamol was associated with a
decrease in the excretion of 16alpha, 17beta-estriol 17-
beta-D-glucuronide (Table 6) suggesting a competition
between paracetamol and endogenous steroid for this
reaction. Contributions of N-acetylcysteine and cysteine
Table 5 Urinary metabolites that are detected only at d14
(positive and negative ion modes)
RT m/z Identification
3.8 447.119 Cysteine paracetamol glucuronideb
4.2 328.103 Paracetamol glucuronidea
4.7 271.075 Cysteine paracetamola
5.1 152.063 Paracetamola
5.5 358.130 3-Methoxy-paracetamol glucuronideb
5.5 281.125 Benzothiazine compoundb
5.9 248.031 Hydroxy-paracetamol sulfatec
6.3 232.031 Paracetamol sulfatea
6.6 449.045 Unknownd
7.7 313.091 N-acetylcysteine paracetamola
9.3 198.063 C9H11NO4
d
RT retention time, m/z mass-to-charge ratio
a Identified compounds (identification with chemical reference
standards)
b Putatively annotated compounds (e.g. without chemical
reference standards, based upon physicochemical properties
and/or spectral similarity with public/commercial spectral
libraries)
c Putatively characterized compound classes (e.g. based upon
characteristic physicochemical properties of a chemical class of
compounds, or by spectral similarity to known compounds of a
chemical class)
d Unknown compounds—although unidentified or unclassified
these metabolites can still be differentiated and quantified based
upon spectral data
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conjugates to paracetamol excretion are in the range of
published values (Forrest et al. 1982; Critchley et al.
1986). In elderly, phase II reactions (conjugation) seem
to be more preserved than phase I reactions (Benedetti
et al. 2007). Therefore, the low excretion of para-
cetamol as sulfate conjugate appears to be due to a low
availability of the sulfate donor, 3′-phosphoadenosine
5′-phosphosulfate, whose precursor is inorganic sulfate
issued from cysteine catabolism. The hepatic supply of
3′-phosphoadenosine 5′-phosphosulfate has already
been suggested to be depleted with a single dose of
3 g compared to 0.5 g paracetamol (Slattery et al.
1987). Despite the fact that fasting plasma sulfates were
not altered by paracetamol treatment (Table 3), a
transient decrease in peripheral/tissular sulfates could
have occurred. Indeed serum sulfates has been reported
to decrease 2 h after administration of paracetamol to
mice (Hazelton et al. 1986). The hepatic pool of sulfate
and/or activities of hepatic 3′-phosphoadenosine 5′-
phosphosulfate synthetic enzymes should have been the
limiting factor(s). Unfortunately, the effect of aging on
these activities is not documented.
Table 6 Urinary metabolites that are modified by paracetamol treatment
RT m/z P value Formula Identification Treatment effect
Positive ion mode
0.6 424.904 0.038 ? Unknownd –
0.7 136.049 0.012 C4H9NO2S Homocysteine
a –
0.9 142.087 0.040 C6H11N3O L-histidinol
b –
1.9 212.062 0.011 ? Unknownd –
2.4 111.010 0.038 ? Unknownd +
2.6 262.043 0.035 C9H12NO6P Phosphotyrosine
b –
3.0 367.162 0.036 ? Unknownd –
3.7 95.016 0.055 C2H6O2S Dimethylsulfone
c +
4.3 224.009 0.016 ? Unknownd +
4.5 151.060 0.003 C5H10O5 Unknown
d –
4.6 166.043 0.001 C5H11NO3S Methioninesulfoxide
b +
7.4 262.043 1.4 E-05 C9H12NO6P 4,6-Diamino-5-formamidopyrimidine
c +
8.8 326.121 0.016 C11H19NO10 N-glycoloyl-neuraminate
c –
9.6 346.230 0.031 ? Unknownd +
10 289.124 0.011 ? Unknownd +
11.4 464.203 0.023 C24H31O9 16alpha,17beta-estriol17-beta-D-glucuronide
b –
11.5 255.128 0.039 C18H22O 3-Deoxyestrone
b –
20.3 472.375 0.042 ? Unknownd –
Negative ion mode
6.9 178.047 0.001 C9H9NO3 Hippurate
a –
6.9 410.018 0.020 C13H15O13S Unknown
d –
11.8 481.248 0.027 C19H38N4O10 Unknown
d –
13.2 465.240 0.004 ? Unknownd –
RT retention time, m/z mass-to-charge ratio
a Identified compounds (identification with chemical reference standards)
b Putatively annotated compounds (e.g. without chemical reference standards, based upon physicochemical properties and/or spectral
similarity with public/commercial spectral libraries)
c Putatively characterized compound classes (e.g. based upon characteristic physicochemical properties of a chemical class of
compounds, or by spectral similarity to known compounds of a chemical class)
d Unknown compounds—although unidentified or unclassified these metabolites can still be differentiated and quantified based upon
spectral data
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Paracetamol treatment and sulfur-containing
compounds
Based on the literature, diminutions in the peripheral
concentrations in sulfur-containing compounds (GSH,
sulfur amino acid, sulfate) were expected to be
induced by the long-term treatment of paracetamol.
In the present study, blood and plasma compounds
were quantified in fasting state, i.e., about 14 h after
evening meal and third daily ingestion of para-
cetamol. Meal and paracetamol post-ingestion kinet-
ics would have been more powerful to evaluate these
alterations. Kinetics measurements were not per-
formed for ethical reasons: elderly subjects were
suffering. In volunteers aged 18 to 40 years, baseline
plasma cysteine, cystine, reduced and oxidized forms
of GSH concentrations were unchanged after 2 day of
paracetamol treatment at the dose of 1 g/day
(Mannery et al. 2010). Nevertheless, in the latter
study some differences appeared significant at some
time-points across the 12-h kinetics. Therefore the
lack of differences in baseline concentrations of
peripheral sulfur-containing compounds does not
mean that intensities of their metabolic pathways
were not affected in the present study. These
modifications are confirmed by the increase in the
dietary intake of proteins, by the quantity of sulfur
excreted into urines to support paracetamol detoxifi-
cation and by modifications in endogenous sulfur-
containing compounds in urine.
Nutritional adjustment to paracetamol treatment
The major adjustment occurring in older persons
under long-term paracetamol treatment was an in-
crease in dietary protein intake with maintenance of
energy intake (Table 2). Before treatment, dietary
protein intake was 0.93±0.08 g/kg/day protein, which
is lower than values reported for French healthy
persons of mean age 68 y (1.2 g/kg/day; Rousset et al.
2003) and for +70-year-old Americans (1.0 g/kg/day;
Fulgoni 2008). This can be explained by their quite
low-energy intake (23 kcal/kg/day), likely due to their
low level of physical activity. The increase in dietary
proteins up to 1.06±0.07 g/kg/day was mainly
focused on animal proteins, which contain more
sulfur amino acid than vegetable proteins do (Block
and Weiss 1956). This increase did not happen for
energetic purpose since energy intake was maintained
by decreasing alcohol (Table 2) and carbohydrates
(not shown) intakes. The increased intake in proteins,
especially from animal sources, most likely occurred
to satisfy the paracetamol-induced increase in sulfur
amino acid demand. The extra-ingestion of sulfur
amino acids was evaluated at 0.30 g/day, which
corresponded to 72 mg/day sulfur. This amount
equaled half of the sulfur excreted in urines as
paracetamol conjugates. Considering that dietary
proteins contain 35 mg of sulfur amino acid/g of
protein (Patureau Mirand 2003), older persons treated
with paracetamol consumed 37 mg sulfur amino acid/
kg/day, which is much higher than the published
population-safe intakes of 21–27 mg/kg/day (Di
Buono et al. 2001; Kurpad et al. 2003). The increase
in dietary proteins probably allowed saving whole
body proteins. Indeed the urinary excretion of
nitrogen converted to proteins (N×6.25) was not
significantly different from the dietary protein intake.
In addition, fasting amino acids were also unchanged
and the large-scale metabolomic analysis did not
reveal significant variation in 3-methylhistidine, a
marker of proteolysis.
Metabolic effects of paracetamol treatment
Despite the adjustment to long-term paracetamol
treatment through the increase in protein intake, the
large-scale analysis of urinary metabolites revealed a
decrease in homocysteine and hippurate supporting an
increased endogenous synthesis of cysteine. The
variation of hippurate, which is a metabolite of
glycine, can be related to endogenous synthesis of
cysteine. Indeed, cysteine synthesis requires serine
which can be synthesized from glycine. Decreased
hippurate has already been reported in urine from rats
receiving paracetamol (Sun et al. 2008). The in-
creased excretion of dimethyl sulfone and methionine
sulfoxide meant that oxidation of sulfur-containing
compounds occurred, likely as a consequence of
decreased antioxidant capacities of cysteine and
GSH. This is supported by the observation that
paracetamol treatment oxidized the plasma cysteine/
cystine redox potential in human (Mannery et al.
2010). An increased oxidative stress could have
clinical effect, since oxidative stress has been impli-
cated in the pathogenesis of cancer, diabetes mellitus,
atherosclerosis, neurodegenerative diseases, rheuma-
toid arthritis, ischemia/reperfusion injury, obstructive
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sleep apnea, other diseases, and also in senescence
(Dröge 2002).
We speculate that whole body proteins would have
been mobilized if older persons under paracetamol
had not increased their sulfur amino acid ingestion.
Assuming that skeletal muscle proteins would have
been mobilized to provide 0.30 g/day sulfur amino
acids for 14 days, the protein loss would have been
issued from 470 g of skeletal muscle, based on 20%
proteins in muscles and 4.5% sulfur amino acids in
muscle proteins (Block and Weiss 1956). The amount
of proteins that should be mobilized to detoxify 3 g/
day paracetamol for 14 days can be estimated from
the ratio between sulfur and nitrogen measured in
urine. Daily sulfur contained in urinary paracetamol
metabolites corresponded to 2.47 g/day nitrogen. This
amount would necessitate the mobilization of 216 g
of protein (N×6.25) over the period of treatment,
corresponding to 1 kg of skeletal muscle. Post-
operative patients treated with paracetamol, and
receiving no nutrients for few days, would face
similar situation. Long-term treatment with other
drugs whose detoxification requires sulfate and
glutathione detoxification might also led to such
alterations.
Study limitations
There are several potential limitations to our study, which
should be acknowledged. As we performed the experi-
ment in independently living older patients, our results
might be not applicable to other older persons, especially
nursing home and long-term care residents and hospital-
ized patients. A lower liver volume and a lower urinary
clearance of paracetamol glucuronide (single intravenous
0.5 g dose) have been reported in frail hospitalized
elderly, compared to fit elderly or young subjects (Wynne
et al. 1990). Nevertheless, no paracetamol accumulation
appeared to occur in polymedicated very old patients
(Bannwarth et al. 2001).The major problem for frail
elderly would be their inability to adjust through an
increase in dietary protein intake. Consequently, body
proteins are expected to be mobilized to support
paracetamol detoxification in this population. The
accuracy of dietary evaluations depends on the quality
of reporting made by patients and the contents of dietary
composition database. Careful interviews were per-
formed by a dietician in order to increase the accuracy
in food intake evaluation at both time points. There is
also a potential bias with respect to large-scale
metabolomic approach due to the comparison of the
second morning urine at the beginning of the treatment
and the 24-h urine at the end. The lack of dietary
standardization might have increased inter-individual
variability and hide some tenuous variations for
endogenous metabolites (Winnike et al. 2009). Never-
theless, a standardization of the diet would have
introduced another bias regarding the spontaneous
modification in animal protein intake. Paracetamol
therapeutic dose was 3 g/day, which is in the line with
French recommendation. Food and Drug Administration
of USA (FDA) has asked for a limited daily dose of
2.6 g a day of paracetamol (see www.fda.gov/med-
watch) while 4 g had been allowed in industrialized
countries. This decision led to a controversy (Graham et
al. 2010). Our results plead for a careful evaluation of
paracetamol needs and individualized dosages depend-
ing on the clinical state of the patient, especially the
elderly. However, paracetamol presents definitely less
side effects than nonsteroidal anti-inflammatory drugs
on a long-term basis and should be used for its valuable
analgesic properties.
Conclusion
Despite a quite low excretion of paracetamol as
sulfate conjugate in independently living older
patients, the amount of sulfur needed to detoxify
3 g/day paracetamol equaled 20% of the sulfur
provided by 1.06 g/kg/day dietary proteins. Their
whole body protein stores were preserved at d14.
Nevertheless, some metabolic deteriorations occurred
(decreased elimination of endogenous steroids, en-
hanced oxidation of sulfur-containing compounds,
and others non-identified modifications), whose phys-
iological consequences are to be determined. Oxida-
tion of sulfur-containing compounds was likely due to
decreased anti-oxidative capacities of cysteine and
glutathione induced by their high utilization for
detoxification purpose. Older persons adjusted to
long-term paracetamol treatment by increasing their
dietary protein intake (mainly those from animal
origin) confirming that usual consumption was insuf-
ficient. The sulfur amino acid daily intake was
adjusted at 37 mg/kg/day, which is much higher than
the corresponding published population-safe intakes.
It appears that nutritional adjustments should be made
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to compensate for the possible deficits induced by
paracetamol consumption. The benefit/risk ratio of
this drug might be largely increased by nutritional
adaptations and guidelines.
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